# Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

> **NCT01353638** · PHASE1,PHASE2 · TERMINATED · sponsor: **Christoph Aufricht** · enrollment: 25 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Dipeptiven (Alanyl-glutamine-dipeptide)

## Key facts

- **NCT ID:** NCT01353638
- **Lead sponsor:** Christoph Aufricht
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-05
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim analysis; a method of increased sensitivity had to be established.
- **Last updated:** 2015-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353638, "Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01353638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*